Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 10:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 218 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Index Event Clear all
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Bridge to Orthotopic Liver Transplantation (OLT) - Surefire Precision vs Endhole Embolization With DEBTACE

NCT03170869
View directory record Official record
Conditions
Hepatocellular Carcinoma of the Liver, Subjects Eligible for Liver Transplantation
Interventions
Surefire Precision Infusion System
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Oct 23, 2026, 10:15 PM EDT
Completed Phase 3 Interventional Results available

Recombinant Human Antithrombin (rhAT) in Patients With Hereditary Antithrombin Deficiency Undergoing Surgery or Delivery

NCT00110513
View directory record Official record
Conditions
Antithrombin III Deficiency
Interventions
Recombinant human antithrombin (rhAT)
Biological
Lead sponsor
rEVO Biologics
Industry
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
New Haven, Connecticut • St Louis, Missouri • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2012 · Synced Oct 23, 2026, 10:15 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

LPFC Organization in Emotion-Duration Difference Estimation

NCT06276400
View directory record Official record
Conditions
Healthy
Interventions
Emotion valence, Time, TMS Stimulation
Other · Device
Lead sponsor
University of California, Santa Barbara
Other
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 23, 2026, 10:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex

NCT00411619
View directory record Official record
Conditions
Tuberous Sclerosis, Subependymal Giant Cell Astrocytoma
Interventions
Everolimus
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 20, 2014 · Synced Oct 23, 2026, 10:15 PM EDT
Completed No phase listed Observational

A Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events

NCT03479736
View directory record Official record
Conditions
Retinal Detachment, Achilles Tendon, Aneurysm, Dissecting
Interventions
Oral Fluoroquinolones (FQ), Other Antibiotics, Febrile Illness Not Treated with Antibiotics Will be Analyzed as an Exposure
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
117,911 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 23, 2026, 10:15 PM EDT
Completed Phase 3 Interventional Results available

Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)

NCT03988634
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
sacubitril/valsartan, valsartan, sacubitril/valsartan matching placebo, valsartan matching placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
87
States / cities
Irvine, California • Long Beach, California • Los Angeles, California + 77 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 23, 2026, 10:15 PM EDT
Completed No phase listed Observational

Skin Tracker: A Mobile Health App to Monitor Skin Disease Activity and Treatment Use

NCT04404075
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
SkinTracker Mobile App
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
13 Years and older
Enrollment
11 participants
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Oct 23, 2026, 10:15 PM EDT
Completed Not applicable Interventional Results available

Improving Treatment Outcomes for Suicidal Veterans With PTSD

NCT04690582
View directory record Official record
Conditions
Suicidal Ideation, Suicide, Attempted, Ptsd
Interventions
Cognitive Processing Therapy (CPT), Crisis Response Plan (CRP), Safety Planning Intervention (SPI), Narrative Assessment
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 23, 2026, 10:15 PM EDT
Withdrawn No phase listed Observational

Neurocardiac Interactions Evaluated by Anatomic and Physiologic MRI Assessment

NCT02962154
View directory record Official record
Conditions
Ischemia, Stress, Mental
Interventions
Coronary CT Angiography, Mood Symptom Scale, Anxiety Symptom Scale, Chronic Stress Inventories, Psychosocial Function Questionnaires, General Health and quality of life questionnaires, Magnetic Resonance Imaging
Radiation · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Oct 23, 2026, 10:15 PM EDT
Not listed No phase listed Observational

Renal Autotransplantation; Case Series

NCT05115812
View directory record Official record
Conditions
Renal Vascular Disease, Nutcracker Syndrome, Renal, Pelvic Trauma, Loin Pain-Hematuria Syndrome, Renal Tumor, Congestion, Venous
Interventions
Pre-Operative Information, Intra-Operative Data, Post-Operative Data (up to discharge), Short-Term Follow-Up Data
Procedure · Other
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 23, 2026, 10:15 PM EDT
Completed Phase 2 Interventional Results available

Blood Pressure After Endovascular Stroke Therapy-II

NCT04116112
View directory record Official record
Conditions
Acute Stroke, Endovascular Thrombectomy
Interventions
Nicardipine, Labetalol, Hydralazine
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Hartford, Connecticut • Cincinnati, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Oct 23, 2026, 10:15 PM EDT
Active, not recruiting Phase 3 Interventional

Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)

NCT05454280
View directory record Official record
Conditions
Surgery, Cancer
Interventions
Intensified post-discharge surveillance, Standard post-discharge surveillance
Procedure
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 23, 2026, 10:15 PM EDT
Recruiting Not applicable Interventional

Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial

NCT04419480
View directory record Official record
Conditions
Cardiogenic Shock, Heart Failure, Ambulatory Hemodynamic Monitoring
Interventions
CardioMEMS implantation with routine ambulatory pulmonary artery pressure monitoring and medication optimization
Device
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 23, 2026, 10:15 PM EDT
Not listed No phase listed Observational

Prospective Single-Timepoint Huntington's Disease Biospecimen Collection Study

NCT05773196
View directory record Official record
Conditions
Huntington Disease, Huntington's Dementia, Huntington Disease, Late Onset, Huntington; Dementia (Etiology)
Interventions
Biospecimen Collection
Other
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
25 Years to 65 Years
Enrollment
5 participants
Timeline
2023 – 2025
U.S. locations
1
States / cities
Woburn, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 23, 2026, 10:15 PM EDT
Completed Phase 3 Interventional

Carotid Artery Revascularization Using the Boston Scientific EPI Filter Wire EZ™ and the EndoTex™ NexStent™

NCT00600327
View directory record Official record
Conditions
Transient Ischemic Attack, Thromboembolic Stroke, Stroke Prevention
Interventions
EndoTex™ NexStent™, Filter Wire EZ™
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
15
States / cities
Phoenix, Arizona • Mountain View, California • Newport Beach, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2008 · Synced Oct 23, 2026, 10:15 PM EDT
Completed Not applicable Interventional Results available

Effect of Caloric Restriction on Fat Oxidation in Obese Men and Women (Magellan II)

NCT01616082
View directory record Official record
Conditions
Obesity, Overweight, Metabolic Diseases
Interventions
Low Calorie Diet (LCD), Phentermine
Behavioral · Drug
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 23, 2026, 10:15 PM EDT
Completed Not applicable Interventional Results available

Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens

NCT01653847
View directory record Official record
Conditions
End Stage Renal Failure With Renal Transplant
Interventions
Tacrolimus with MMF, Group 2: Tacrolimus with Everolimus.
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 70 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Oct 23, 2026, 10:15 PM EDT
Completed No phase listed Observational

PPCM Observational Study (Peripartum Cardiomyopathy)

NCT04234659
View directory record Official record
Conditions
Peripartum Cardiomyopathy, Cardiogenic Shock
Interventions
Clinical placement of a temporary IMPELLA® mechanical circulatory support device.
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 23, 2026, 10:15 PM EDT
Completed Phase 3 Interventional Results available

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

NCT02876835
View directory record Official record
Conditions
Anaemia
Interventions
Daprodustat, Darbepoetin alfa, Placebo, Iron Therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 99 Years
Enrollment
3,872 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
161
States / cities
Andalusia, Alabama • Birmingham, Alabama • Huntsville, Alabama + 128 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 23, 2026, 10:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Text Message Intervention for Alcohol Use and Sexual Violence in College Students

NCT05065918
View directory record Official record
Conditions
Alcohol Use, Unspecified, Sexual Violence, Sexual Assault
Interventions
sexual violence and alcohol use harm reduction text message content, alcohol use reduction content
Behavioral
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 24 Years
Enrollment
183 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 23, 2026, 10:15 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

NCT05601882
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years to 64 Years
Enrollment
920 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
58
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • North Little Rock, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Oct 23, 2026, 10:15 PM EDT
Completed Phase 2 Interventional Results available

Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study

NCT00940602
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Deferasirox, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
11
States / cities
Anaheim, California • Greenwood Village, Colorado • Shreveport, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 23, 2026, 10:15 PM EDT
Completed No phase listed Observational

Can Sleep Apnea Screening Questionnaire Predict Adverse Events in Endoscopic Studies

NCT03436381
View directory record Official record
Conditions
Sleep Apnea, Adverse Event
Interventions
Questionaire
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
350 participants
Timeline
2018 – 2021
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 23, 2026, 10:15 PM EDT
Completed Phase 3 Interventional Results available

Comparative Study of Modified Release (MR) Tacrolimus/Mycophenolate Mofetil (MMF) in de Novo Kidney Transplant Recipients

NCT00064701
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Tacrolimus Modified Release (MR), Tacrolimus, cyclosporine microemulsion, mycophenolate mofetil
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
12 Years and older
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
48
States / cities
Birmingham, Alabama • Mobile, Alabama • Loma Linda, California + 36 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2013 · Synced Oct 23, 2026, 10:15 PM EDT